| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
1 Molecular Oncology Group, McGill University Health Center, Departments of 2 Biochemistry, 3 Oncology, 4 Medicine, 5 Microbiology and Immunology, 6 Human Genetics, and 7 Pathology, McGill University; 8 McConnell Brain Imaging Centre, Montreal Neurological Institute; and Departments of 9 Pathology and 10 Microbiology, Faculty of Veterinary Medicine, Université de Montréal, Montreal, Quebec, Canada
Requests for reprints: Alain Nepveu, Molecular Oncology Group, McGill University, 687 Pine Avenue West, Room H5.21, Montreal, Quebec, Canada H3A 1A1. Phone: 514-934-1934 ext. 35842; Fax: 514-843-1478; E-mail: alain.nepveu{at}mcgill.ca.
The p75 CCAAT-displacement protein/Cut homeobox (CDP/Cux) isoform was previously reported to be overexpressed in human breast cancers. To investigate its oncogenic potential, we engineered two transgenic mouse lines expressing p75 CDP/Cux under the control of the mouse mammary tumor virus-long terminal repeat. The FVB strain of mouse is generally used in the generation of mouse models for breast cancer. The transgene was introduced into the hprt locus of 129/Ola embryonic stem cells and, following germ line passage, was backcrossed onto the FVB and C57BL/6 mouse strains. Here, we describe the phenotype of p75 CDP/Cux transgenic virgin female mice of the first backcross generations. We report that after a long latency period,
33% of mice from two independent transgenic lines and from backcrosses into either the FVB or the C57BL/6 strains succumbed to a similar disease characterized by splenomegaly, hepatomegaly, and frequent infiltration of leukocytes into nonhematopoietic organs like the kidneys and lungs. Although an excess of B or T cells was observed in three diseased mice, in 17 other cases, histologic and flow cytometry analyses revealed the expansion of a population of neutrophils in the blood, spleen, and bone marrow. The increase in neutrophils correlated with signs of anemia and thrombocytopenia, whereas there was no indication of a reactive process. Therefore, p75 CDP/Cux transgenic mice displayed heightened susceptibility to a disease defined as a myeloproliferative diseaselike myeloid leukemia. These results indicate that the overexpression of p75 CDP/Cux could alter homeostasis in the hematopoietic compartment. (Cancer Res 2006; 66(19): 9492-501)
This article has been cited by other articles:
![]() |
C. Cadieux, V. Kedinger, L. Yao, C. Vadnais, M. Drossos, M. Paquet, and A. Nepveu Mouse Mammary Tumor Virus p75 and p110 CUX1 Transgenic Mice Develop Mammary Tumors of Various Histologic Types Cancer Res., September 15, 2009; 69(18): 7188 - 7197. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Cadieux, R. Harada, M. Paquet, O. Cote, M. Trudel, A. Nepveu, and M. Bouchard Polycystic Kidneys Caused by Sustained Expression of Cux1 Isoform p75 J. Biol. Chem., May 16, 2008; 283(20): 13817 - 13824. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Truscott, R. Harada, C. Vadnais, F. Robert, and A. Nepveu p110 CUX1 Cooperates with E2F Transcription Factors in the Transcriptional Activation of Cell Cycle-Regulated Genes Mol. Cell. Biol., May 15, 2008; 28(10): 3127 - 3138. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Goulet, Y. Markovic, L. Leduy, and A. Nepveu Proteolytic Processing of Cut Homeobox 1 by Neutrophil Elastase in the MV4;11 Myeloid Leukemia Cell Line Mol. Cancer Res., April 1, 2008; 6(4): 644 - 653. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Harada, C. Vadnais, L. Sansregret, L. Leduy, G. Berube, F. Robert, and A. Nepveu Genome-wide location analysis and expression studies reveal a role for p110 CUX1 in the activation of DNA replication genes Nucleic Acids Res., January 17, 2008; 36(1): 189 - 202. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Goulet, L. Sansregret, L. Leduy, M. Bogyo, E. Weber, S. S. Chauhan, and A. Nepveu Increased Expression and Activity of Nuclear Cathepsin L in Cancer Cells Suggests a Novel Mechanism of Cell Transformation Mol. Cancer Res., September 1, 2007; 5(9): 899 - 907. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |